Episode 67
Biotech Hangout
00:00
Gilead and the HIV Platform
The New York Times accused Gilead of slow walking development of newer versions of HIV therapies in order to extend the patent protection on them. Matt, I'm sure you have an opinion on this because part of your business model is to take things that is sitting on the shelf in large pharmaceutical companies and add new energy and effort into them. What's your opinion when you see a big deal like this? "We follow these things with interest and try to do the best we can"
Transcript
Play full episode
